Family Heart Foundation

U.S. non-profit for FH and Lp(a) advocacy, research, education to prevent heart disease.

Also known as FH Foundation and The FH Foundation.

Latest news on Family Heart Foundation

16 July 2026

Merck’s LIPFENDRA — first FDA‑approved once‑daily oral PCSK9 inhibitor

Oral macrocyclic peptide enlicitide (20 mg) lowers LDL-C ~56–59% at week 24 in Phase 3 trials; approved as adjunct to diet and exercise for adults with hypercholesterolemia, including HeFH.